A recent Klimas/Broderick study had a lot of interesting things in it: the gender divide, and the illumination of possibly key immune and metabolic factors, but the most intriguing thing about the study was its potential precision.
The study possibly identified specific pathways associated with a powerful cytokine that could be tweaked with drugs to help people with ME/CFS. While much more study is needed, no one has developed this precise of an approach to treatment before. One hopes this is the future for ME/CFS.
Find out more in this Simmaron Research Foundation sponsored blog:
New Pathways: A Step Towards Fine-Tuning Treatments for ME/CFS?
A novel drug called “Filgotinib” has just been approved in Europe. This is a Belgian drug, a so called JAK inhibitor. It has also some in treating CFS (there is a clinic, which plans to use this):
Filgotinib is totally new, the cost is probably very high. Side effects not very much known. It is also telling that placebo had a comparable efficacy (20% vs. 48%).
What do you mean with the comparable efficacy ?
20% versus 48% is quite a difference no?
OK, that is quite a difference. I was just gonna say that 20% is high enough too what a placebo is concerned. We are talking about remission.
Which clinic plans to use filogitnib for ME/CFS?
You have a link to the study or trial page?
Which clinic plan to use it?
This article is about JAK pathway. This is why I commented.
Hey Cort? At one time you were making a point of providing a bullet point summary for those of us who struggle with reading a lot of text. Would you please consider making that a standard for your articles? It would make it much easier for me to at least get the gist of things, and I don’t think I’m alone. Thanks for your kind consideration!
Thanks for the reminder 🙂